Able Partners

Able Partners is a New York firm that has been quietly assembling one of the more coherent early-stage portfolios in consumer health, mental health, and women’s health for nearly a decade. Founded in 2016 by Lisa Blau and Amanda Eilian, Able operates with a thesis that takes consumer behavior as a serious input rather than an afterthought, an orientation that sets it apart from the broader healthtech investor cohort that tends to start every diligence conversation at the payer contract. Able’s founders bring operating and consumer-brand backgrounds that translate into a genuine empathy for the messy work of building products people actually want to use. For founders building at the intersection of healthcare and modern consumer experience, the firm is one of the most credible early addresses in the United States.

The thesis spans wellness and consumer health, mental and behavioral health, women’s and reproductive health, and digital health. What ties these together is a focus on companies that combine credible clinical or scientific substance with a consumer-grade product experience. Able is comfortable with category-defining brand bets in spaces where competitors are still operating like medical device makers, and it is equally comfortable with clinical-services companies that need to learn consumer marketing. The firm pays particular attention to founder narrative, brand voice, and the realism of the path from a passionate early customer base to a durable business model. It tends to be skeptical of pure direct-to-consumer plays without a defensible clinical or behavioral wedge, and it rewards founders who can articulate what changes in a customer’s life when the product works.

The portfolio includes Maven Clinic, Oura, Spring Health, and Alma, four of the more important companies in modern women’s health, consumer wearables, mental health benefits, and provider-enablement for therapy respectively. The pattern across these names is instructive: Able tends to be early on companies that ultimately become category leaders in spaces previously underserved by venture, and it tends to back founders who are obsessive about user experience as a core part of the medical product. Founders evaluating Able should expect to be benchmarked, implicitly, against the bar these companies set on consumer love, retention, and brand equity. The firm is willing to underwrite a longer build cycle on companies that are creating new categories rather than competing on a checklist of features.

Check sizes typically fall in the one to five million dollar range, with the firm participating at seed and Series A, sometimes leading and often co-leading alongside larger institutional partners. Able is willing to take meaningful early ownership but is not a fund-returner-or-bust shop; it has the patience to support companies through the long build that consumer health requires. Reserves are deployed selectively into the portfolio’s strongest performers, and founders should expect Able to be a thoughtful participant in subsequent rounds rather than a passive name on the cap table.

Decision-making sits with the founding partners Lisa Blau and Amanda Eilian, supported by a small investment team. The firm operates with the cadence of a high-touch early-stage shop. Conviction tends to form through a small number of substantive conversations in which founders should expect to discuss not only the business model but the texture of the customer experience, the brand they intend to build, and the values the company will operate by. Able is openly values-driven, and that orientation shapes the diligence process and the post-investment relationship.

The right approach is a warm introduction from a portfolio founder, a brand or consumer operator the firm respects, or a co-investor with shared history in consumer health. Cold outreach can work when a founder leads with a clear consumer insight, real early usage data, and a credible team. Founders should arrive prepared to talk about retention cohorts, qualitative customer feedback, and brand positioning, not just the size of the underlying healthcare market.

What founders should know is that Able Partners is a high-signal early check for companies building at the intersection of healthcare and consumer experience. Founders chasing a pure enterprise contract without a consumer dimension will find a less natural fit. Founders building products that people genuinely want to use, in categories where consumer love is a competitive moat, will find Able one of the most thoughtful partners in the market.